All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Phyllodes tumors (PT) are biphasic tumors accounting for 0.3--1.5% of all breast tumors. The World Health Organization (WHO) classifies PTs as benign, borderline, and malignant based on the evaluation of the stromal component \[[@pone.0238466.ref001]\]. PTs can recur and metastasize heterogeneously \[[@pone.0238466.ref001]\]. Although their stromal component is considered the main neoplastic element in PT \[[@pone.0238466.ref002]\], epithelial-stromal interaction is also thought to be involved in PT pathogenesis. The epithelial-stromal interaction of PTs is suggested to involve the Wnt pathway \[[@pone.0238466.ref003]\], platelet-derived growth factor (PDGF)/PDGF receptor(R)-β pathway \[[@pone.0238466.ref004]\], insulin-like growth factor (IGF)-I/II \[[@pone.0238466.ref005]\], and C-X-C receptor type 4 (CXCR4) \[[@pone.0238466.ref006]\]. The MED12 mutation is also known as a driver of tumorigenesis in fibroepithelial tumors \[[@pone.0238466.ref007], [@pone.0238466.ref008]\]. Recently, two mechanisms are suggested to underlie the progression of the histologic grade of PT: fibroepithelial tumor and benign PT show frequent somatic MED12 mutation and additional genetic alterations are found with increasing histologic grade, whereas borderline/malignant PTs without MED12 mutation frequently harbor TP53 and PIK3CA mutations \[[@pone.0238466.ref009], [@pone.0238466.ref010]\].

Epithelial membrane proteins (EMPs; EMP1, EMP2, and EMP3) are members of the peripheral myelin protein (PMP22) gene family \[[@pone.0238466.ref011]\]. EMP1 is a target of c-MYC \[[@pone.0238466.ref012]\], and is highly expressed in undifferentiated cells \[[@pone.0238466.ref013]\]; it has been reported as a negative regulator in some cancers including nasopharyngeal cancer \[[@pone.0238466.ref014]\], and breast cancer \[[@pone.0238466.ref015]\]. EMP2 has been considered an oncogene, particularly in hormone-related cancers such as endometrial and breast cancer \[[@pone.0238466.ref016], [@pone.0238466.ref017]\]. EMP3 appears to be a tumor suppressor gene in solid tumors \[[@pone.0238466.ref018]\]. So far, EMPs have been evaluated in various malignant tumors, particularly, brain tumors and carcinomas. However, EMP expression in breast PTs has not been elucidated. As PT is a biphasic neoplasm, EMP expression in both epithelial and stromal components, as well as in different histologic grades, is expected to differ. In the present study, we aimed to evaluate the expression and clinical implications of EMP1, EMP2, and EMP3 in breast PTs.

Materials and methods {#sec006}
=====================

Patient selection {#sec007}
-----------------

Tissue samples were collected from patients with a pathologically confirmed diagnosis of PT who underwent resection at the Severance hospital between 2000 and 2010. The study was approved by the Institutional review board of Yonsei university, Severance hospital, with wavier of informed consent. All clinical data were anonymized. All tissues were fixed in 10% buffered formalin and embedded in paraffin. All archival hematoxylin and eosin (H&E)-stained slides for each case were reviewed by two pathologists (JS Koo and YJ Cha), and all PTs were assigned a histologic grade based on the WHO classification \[[@pone.0238466.ref001]\]. Clinical factors including patient age at diagnosis, tumor recurrence, distant metastasis, and patient survival were examined.

Tissue microarray {#sec008}
-----------------

On H&E-stained slides of tumors, a representative area was selected, and the corresponding spot was marked on the surface of the paraffin block. Using a biopsy needle, the selected area was punched out and the resulting 5-mm tissue core was placed in a 5 × 6 recipient block. Two tissue cores were extracted from each case to minimize extraction bias. Each separate tissue core was assigned a unique tissue microarray location number that was linked to a database including other clinicopathologic data.

Immunohistochemistry and interpretation {#sec009}
---------------------------------------

The antibodies used for immunohistochemistry in this study are shown in [Table 1](#pone.0238466.t001){ref-type="table"}. All immunostaining procedures were performed using formalin-fixed, paraffin-embedded tissue sections. Briefly, 5-μm-thick sections were prepared using a microtome, transferred to adhesive slides, and dried at 62°C for 30 minutes. After incubation with primary antibodies, immunodetection was performed with biotinylated anti-mouse immunoglobulin, followed by peroxidase-labeled streptavidin using a labeled streptavidin biotin kit with 3,3′-diaminobenzidine as the chromogenic substrate. Appropriate positive and negative controls were included. Slides were counterstained with Harris hematoxylin. The staining of all immunohistochemical markers was assessed by light microscopy and samples were scored by multiplying the proportion of stained cells (0%, negative; 1, \<30% positivity, 2; ≥30% positivity) with the staining intensity (0, negative; 1, weak; 2, moderate; 3, strong). Representative pictures of staining is shown in [S1](#pone.0238466.s001){ref-type="supplementary-material"} and [S2](#pone.0238466.s002){ref-type="supplementary-material"} Figs. Multiplied values of 0 and 1 were considered as negative whereas values of 2 or more were considered as positive \[[@pone.0238466.ref019]\].

10.1371/journal.pone.0238466.t001

###### Source, clone, and dilution of the antibodies used.

![](pone.0238466.t001){#pone.0238466.t001g}

  Antibody   Company                             Clone        Dilution
  ---------- ----------------------------------- ------------ ----------
  EMP1       Abcam, Cambridge, UK                N-terminal   1:100
  EMP2       Abcam, Cambridge, UK                C-terminal   1:100
  EMP3       Santa Cruz Biotechnology, CA, USA   SW-5         1:100

EMP, epithelial membrane protein.

Statistical analysis {#sec010}
--------------------

Data were analyzed using SPSS for Windows, Version 18.0 (SPSS Inc., Chicago, IL, USA). For determination of statistical significance, Student's *t* test and Fisher's exact test were used for continuous and categorical variables, respectively. Statistical significance was considered at *P* \< 0.05. Kaplan-Meier survival curves and log-rank statistics were employed to evaluate the time to tumor recurrence. Multivariate regression analysis was performed using the Cox proportional hazards model.

Results {#sec011}
=======

Basal characteristics of PTs {#sec012}
----------------------------

[Table 2](#pone.0238466.t002){ref-type="table"} shows the basal clinical characteristics of patients. In total, 185 cases were included in this study and were composed of 138 benign, 32 borderline, and 15 malignant PTs. Increasing age and tumor size were associated with the histologic grade of PT (*P* = 0.013, and *P* = 0.001, respectively). Tumor recurrence and distant metastasis were more frequent with higher histologic grade (*P* \< 0.001). Seven PTs showed distant metastasis, and the metastatic site for all cases was the lung ([Table 2](#pone.0238466.t002){ref-type="table"}).

10.1371/journal.pone.0238466.t002

###### Clinicopathologic characteristics of patients with phyllodes tumor.

![](pone.0238466.t002){#pone.0238466.t002g}

  Parameters                          Total N = 185 (%)   PT, benign N = 138 (%)   PT, borderline N = 32 (%)   PT, malignant N = 15 (%)   *P*-value
  ----------------------------------- ------------------- ------------------------ --------------------------- -------------------------- -----------
  Age, years (mean ± SD)              40.4 ± 12.2         39.1 ± 12.1              43.2 ± 11.0                 47.6 ± 13.4                0.013
  Tumor size, cm (mean ± SD)          4.0 ± 2.6           3.7 ± 2.2                4.2 ± 2.5                   6.2 ± 4.3                  0.001
  Stromal cellularity                                                                                                                     \<0.001
   Mild                               107 (57.8)          105 (76.1)               2 (6.3)                     0 (0.0)                    
   Moderate                           66 (35.7)           33 (23.9)                26 (81.3)                   7 (46.7)                   
   Marked                             12 (6.5)            0 (0.0)                  4 (12.5)                    8 (53.3)                   
  Stromal atypia                                                                                                                          \<0.001
   Mild                               143 (77.3)          136 (98.6)               7 (21.9)                    0 (0.0)                    
   Moderate                           32 (17.3)           2 (1.4)                  22 (68.8)                   8 (53.3)                   
   Marked                             10 (5.4)            0 (0.0)                  3 (9.4)                     7 (46.7)                   
  Stromal mitosis (per 10 HPFs)                                                                                                           \<0.001
   0--4                               142 (76.8)          138 (100.0)              4 (12.5)                    0 (0.0)                    
   5--9                               33 (17.8)           0 (0.0)                  28 (87.5)                   5 (33.3)                   
   ≥ 10                               10 (5.4)            0 (0.0)                  0 (0.0)                     10 (66.7)                  
  Stromal overgrowth                                                                                                                      \<0.001
   Absent                             169 (91.4)          138 (100.0)              29 (90.6)                   2 (13.3)                   
   Present                            16 (8.6)            0 (0.0)                  3 (9.4)                     13 (86.7)                  
  Tumor margin                                                                                                                            \<0.001
   Circumscribed                      166 (89.7)          135 (97.8)               25 (78.1)                   6 (40.0)                   
   Infiltrative                       19 (10.3)           3 (2.2)                  7 (21.9)                    9 (60.0)                   
  Surgical procedure                                                                                                                      \<0.001
   Local excision                     136 (73.5)          119 (86.2)               16 (50.0)                   1 (6.7)                    
   Wide excision                      38 (20.5)           14 (10.1)                15 (46.9)                   9 (60.0)                   
   Mastectomy                         11 (5.9)            5 (3.6)                  1 (3.1)                     5 (33.3)                   
  Margin status                                                                                                                           0.928
   Negative                           160 (86.5)          120 (87.0)               27 (84.4)                   13 (86.7)                  
   Positive                           25 (13.5)           18 (13.0)                5 (15.6)                    2 (13.3)                   
  Tumor local recurrence              17 (9.2)            5 (3.6)                  5 (15.6)                    7 (46.7)                   \<0.001
  Distance metastasis                 7 (3.8)             0 (0.0)                  0 (0.0)                     7 (46.7)                   \<0.001
  Follow-up, months (median, range)   63 (8--183)         73 (14--183)             59 (12--144)                15 (8--62)                 \<0.001

PT, phyllodes tumor; SD, standard deviation; HPFs, high power fields.

EMP1, EMP2, and EMP3 expression according to the PT grades {#sec013}
----------------------------------------------------------

The expression of EMP1, EMP2, and EMP3 in both the epithelial and stromal components differed according to the histologic grade ([Table 3](#pone.0238466.t003){ref-type="table"}). EMP1 (*P* = 0.027), EMP2 (*P* = 0.004), and EMP3 (*P* = 0.032) expression in the epithelial component showed an inverse correlation with the histologic grade. In contrast, EMP1 (*P* = 0.027), EMP2 (*P* = 0.004), and EMP3 (*P* = 0.032) expression in the stromal component was higher in borderline and malignant PTs compared to that in benign PTs ([Fig 1](#pone.0238466.g001){ref-type="fig"}).

![Representative histologic images of hematoxylin and eosin staining and immunohistochemical staining for EMP1, EMP2, and EMP3 in phyllodes tumors with different histologic grades.\
The expression of EMPs is the strongest in the epithelial component of benign phyllodes tumors (PT). Notably, strong stromal expression of EMP1, EMP2, and EMP3 is observed in malignant PT.](pone.0238466.g001){#pone.0238466.g001}

10.1371/journal.pone.0238466.t003

###### Expression of EMP1, EMP2, and EMP3 in phyllodes tumors.
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  Parameters                                      Total N = 185 (%)   PT, benign N = 138 (%)   PT, borderline N = 32 (%)   PT, malignant N = 15 (%)   *P*-value
  ----------------------------------------------- ------------------- ------------------------ --------------------------- -------------------------- -----------
  EMP1 (E)[\*](#t003fn001){ref-type="table-fn"}                                                                                                       0.027
   Negative                                       9 (5.4)             5 (3.6)                  3 (11.1)                    1 (33.3)                   
   Positive                                       159 (94.6)          133 (96.4)               24 (88.9)                   2 (66.7)                   
  EMP1 (S)                                                                                                                                            \<0.001
   Negative                                       81 (43.8)           75 (54.3)                3 (9.4)                     3 (20.0)                   
   Positive                                       104 (56.2)          63 (45.7)                29 (90.6)                   12 (80.0)                  
  EMP2 (E)[\*](#t003fn001){ref-type="table-fn"}                                                                                                       0.004
   Negative                                       39 (23.2)           32 (23.2)                4 (14.8)                    3 (100.0)                  
   Positive                                       129 (76.8)          106 (76.8)               23 (85.2)                   0 (0.0)                    
  EMP2 (S)                                                                                                                                            \<0.001
   Negative                                       176 (95.1)          137 (99.3)               26 (81.3)                   13 (86.7)                  
   Positive                                       9 (4.9)             1 (0.7)                  6 (18.8)                    2 (13.3)                   
  EMP3 (E)[\*](#t003fn001){ref-type="table-fn"}                                                                                                       0.032
   Negative                                       24 (14.3)           18 (13.0)                4 (14.8)                    2 (66.7)                   
   Positive                                       144 (85.7)          120 (87.0)               23 (85.2)                   1 (33.3)                   
  EMP3 (S)                                                                                                                                            \<0.001
   Negative                                       137 (74.1)          118 (85.5)               13 (40.6)                   6 (40.0)                   
   Positive                                       48 (25.9)           20 (14.5)                19 (59.4)                   9 (60.0)                   

\*Seventeen tumors without an epithelial component were excluded.

PT, phyllodes tumor; EMP, epithelial membrane protein; E, epithelial staining; S, stromal staining.

Correlation between EMP1, EMP2, and EMP3 expression in PTs and pathologic parameters {#sec014}
------------------------------------------------------------------------------------

Stromal positivity of EMP1 and EMP3 was associated with stromal cellularity and stromal cell atypia. EMP1 expression was positively correlated with increasing stromal cellularity and cellular atypia (*P* \< 0.001, [Fig 2](#pone.0238466.g002){ref-type="fig"}).

![Association of histology and the expression of EMP1 and EMP3.\
Increased stromal cellularity and stromal atypia are correlated with the expression rate of EMP1 (A and B) and EMP3 (C and D) S, stromal.](pone.0238466.g002){#pone.0238466.g002}

Impact of EMP1, EMP2, and EMP3 expression on patient prognosis {#sec015}
--------------------------------------------------------------

In univariate analysis, stromal EMP3 expression was associated with shorter disease-free survival (*P* \< 0.001) and shorter overall survival (OS) (*P* = 0.034) ([Table 4](#pone.0238466.t004){ref-type="table"}, [Fig 3](#pone.0238466.g003){ref-type="fig"}). However, no significant difference for stromal EMP3 expression was found by multivariate Cox analysis ([Table 5](#pone.0238466.t005){ref-type="table"}).

![Disease-free survival and overall survival based on EMP3 expression.\
Cases with stromal EMP3 expression show inferior prognosis with regard to disease-free survival (A) and overall survival (B). S, stromal.](pone.0238466.g003){#pone.0238466.g003}

10.1371/journal.pone.0238466.t004

###### Univariate analysis of the impact of EMP1, EMP2, and EMP3 expression in phyllodes tumors.

![](pone.0238466.t004){#pone.0238466.t004g}

  Parameters                                      No. of patients (%) Total/recurrence/metastasis   Disease-free survival   Overall survival                    
  ----------------------------------------------- ------------------------------------------------- ----------------------- ------------------ ---------------- -------
  EMP1 (E)[\*](#t004fn001){ref-type="table-fn"}                                                                             N/A                                 N/A
   Negative                                       9 (100.0) / 0 (0.0) / 0 (0.0)                     N/A                                        N/A              
   Positive                                       159 (100.0) / 10 (6.3) /1 (0.6)                   N/A                                        N/A              
  EMP1 (S)                                                                                                                  0.364                               N/A
   Negative                                       81 (100.0) / 6 (7.4) / 0 (0.0)                    166 (156--176)                             N/A              
   Positive                                       104 (100.0) / 11 (10.6) / 7(6.7)                  162 (151--174)                             N/A              
  EMP2 (E)[\*](#t004fn001){ref-type="table-fn"}                                                                             0.642                               N/A
   Negative                                       39 (100.0) / 2 (5.1) / 0 (0.0)                    169 (158--179)                             N/A              
   Positive                                       129 (100.0) /8 (6.2) / 1 (0.8)                    171 (163--179)                             N/A              
  EMP2 (S)                                                                                                                  N/A                                 N/A
   Negative                                       176 (100.0) / 17 (9.7) / 7 (4.0)                  N/A                                        N/A              
   Positive                                       9 (100.0) / 0 (0.0) / 0 (0.0)                     N/A                                        N/A              
  EMP3 (E)[\*](#t004fn001){ref-type="table-fn"}                                                                             0.687                               N/A
   Negative                                       24 (100.0) / 2 (8.3) / 0 (0.0)                    134 (119--148)                             N/A              
   Positive                                       144 (100.0) / 8 (5.6) /1 (0.7)                    172 (165--179)                             N/A              
  EMP3 (S)                                                                                                                  \<0.001                             0.034
   Negative                                       137 (100.0) / 7 (5.1) / 3 (2.2)                   173 (167--180)                             179 (174--183)   
   Positive                                       48 (100.0) / 10 (20.8) / 4 (8.3)                  138 (116--159)                             163 (150--176)   

\*Seventeen tumors without an epithelial component were excluded.

PT, phyllodes tumor; EMP, epithelial membrane protein; E, epithelial staining; S, stromal staining.

10.1371/journal.pone.0238466.t005

###### Multivariate Cox regression analysis of disease-free and overall survival in patients with phyllodes tumors.

![](pone.0238466.t005){#pone.0238466.t005g}

  Included factor         Disease-free survival   Overall survival                           
  ----------------------- ----------------------- ------------------ ----------------------- -------
  Histologic grade                                                                           
   Benign                 Reference                                  Reference               
   Borderline/malignant   2.435 (0.536--11.060)   0.249              206.6 (3.929--10866)    0.008
  Stromal cellularity                                                                        
   Mild                   Reference                                  Reference               
   Moderate/marked        1.198 (0.159--9.032)    0.861              0.002 (0.000--8.503)    0.910
  Stromal atypia                                                                             
   Mild                   Reference                                  Reference               
   Moderate/marked        0.800 (0.111--5.774)    0.825              0.000 (0.000--6.754)    0.881
  Stromal mitosis                                                                            
   0-4/10 HPFs            Reference                                  Reference               
   \>4/10 HPFs            9.550 (0.781--116.7)    0.077              16125 (0.000--6.538)    0.857
  Stromal overgrowth                                                                         
   Absent                 Reference                                  Reference               
   Present                3.535 (0.830--15.060)   0.088              30617 (0.000--1.456)    0.862
  Tumor margin                                                                               
   Circumscribed          Reference                                  Reference               
   Infiltrative           0.558 (0.159--1.957)    0.362              0.150 (0.013--1.715)    0.127
  EMP3 (S)                                                                                   
   Negative               Reference                                  Reference               
   Positive               0.523 (0.153--1.787)    0.301              1.841 (0.035--98.090)   0.763

HR, hazard ratio; CI, confidence interval; HPFs, high power fields; EMP, epithelial membrane protein; S, stromal staining.

Discussion {#sec016}
==========

We evaluated the expression of EMP1, EMP2, and EMP3 in PTs of the breast, and found that EMP expression was reduced in the epithelial component and was increased in the stromal component, along with increasing histologic grade. Although the epithelial component showed a different expression pattern--an inverse correlation with stromal expression--we focused on the stromal component in the present study because the stromal component is the neoplastic element and determines the diagnosis and tumor grade. Although PTs account for a far lesser proportion of breast fibroepithelial lesions compared to fibroadenomas, both lesions share histomorphological features \[[@pone.0238466.ref020], [@pone.0238466.ref021]\], as well as genetic alterations such as recurrent MED12 mutations \[[@pone.0238466.ref007], [@pone.0238466.ref022]--[@pone.0238466.ref024]\].

In the present study, stromal EMPs showed significantly increased expression in borderline/malignant PTs, but only stromal EMP3 expression was identified as an independent risk factor for short OS. Considering that EMP1, EMP2, and EMP3 have been reported to play important roles in various malignant tumors \[[@pone.0238466.ref025]\], increased expression of EMP1 and EMP3, along with stromal cellularity and stromal atypia, imply that increased EMP expression in PT could suggest a higher malignant potential for PT. EMP1 also showed a tendency for increased expression in the stroma along with an increase in the histologic grade, but did not impact prognosis. Conversely, stromal EMP2 expression was only found in a few cases (N = 9), no further statistical meaning could be found.

A previous study has shown that EMP3 is hypermethylated in approximately 20--40% of neuroblastoma and glioma cases, and plays a role in tumor suppression, which is also related with patients' prognosis \[[@pone.0238466.ref026]\]. As most previous studies regarding EMPs had used epithelial carcinoma and a few had used glioma, this study was important as it determined the role of EMP3 in non-epithelial tumors, similar to the present study. Another recent study on high-grade glioma showed high expression of EMP3, particularly in CD44-high glioblastoma \[[@pone.0238466.ref027]\], which refuted the result of a prior study on glioma \[[@pone.0238466.ref026]\]. However, CD44-high glioblastoma is different from the general cases of glioma; it is classified as the mesenchymal subclass within glioblastoma. EMP3 expression was found to be correlated with the activation of TGF-β/Smad2/3 signaling by interaction with TGFBR2, which resulted in TGF-β stimulated gene expression and tumor cell proliferation \[[@pone.0238466.ref027]\]. TGF-β signaling generally enhances epithelial mesenchymal transition (EMT) \[[@pone.0238466.ref028], [@pone.0238466.ref029]\], but it also activates the proliferation of tumor cells of non-epithelial origin \[[@pone.0238466.ref030], [@pone.0238466.ref031]\]. In gastric cancer, EMP3 has been suggested as a downstream effector of TWIST1/2 and a regulator of EMT \[[@pone.0238466.ref032]\].

Moreover, a previous study showed that malignant PT was more likely to have wild-type MED12 along with mutations in PIK3CA, which is considered an oncogene \[[@pone.0238466.ref009]\]. EMP3 and EMP1 have been reported to be involved in the PI3K/Akt pathway in HCC \[[@pone.0238466.ref033]\], and in the tumorigenesis of non-small cell lung cancer \[[@pone.0238466.ref034]\]. Because research regarding the treatment of PT is still limited and unclear, mining of effective therapeutic targets is necessary \[[@pone.0238466.ref035], [@pone.0238466.ref036]\]. As stromal EMP3 expression showed increased expression along with the histologic grade as well as was intimately associated with tumor aggressiveness and prognosis in the present study, it might be considered as a good candidate for treatment. Moreover, EMP1 and EMP2, which also showed increased expression in borderline/malignant PT, should be also evaluated further, even though they showed no significant clinical impact in the present study. In the present study, EMP2-expressing PTs were too few in number, and were inappropriate for statistical analysis. However, EMP2 has been reported to be highly expressed in glioblastoma and in human samples and a mouse model; further, the anti-EMP antibody showed efficacy in tumor inhibition \[[@pone.0238466.ref037]\]. Another limitation of the present study is that there is no data evaluates the EMPs in mesenchymal tumors, probably EMPs are basically epithelial membrane proteins, as their names. As anti EMP2 antibody could affect the tumor inhibition of glioblastoma, further evaluation and validation of EMPs expression in high grade mesenchymal tumors are required.

In conclusion, the results of this study indicate that stromal expression of EMP1, EMP2, and EMP3 is increased along with the histologic grade in PT, and that stromal EMP3 expression is an independent prognostic factor for the survival of patients with breast PTs.

Supporting information {#sec017}
======================

###### Scan power view of all immunohistochemistry slides of EMP1, EMP2, and EMP3.

(TIF)

###### 

Click here for additional data file.

###### Higher magnification of immunohistochemistry of EMP1, EMP2, and EMP3.

(TIF)

###### 

Click here for additional data file.
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1. Were the pathologists blind to the identity of the patients, their clinic-pathological diagnoses, and survival data?

2\. Please provide lower magnification images of all the IHC slides -- demonstrating the distribution of EMP staining in the stromal vs epithelial areas.

3\. Please provide higher magnification images of all the IHC slides -- demonstrating cell membranous localization of the EMP proteins.

4\. How was the "proportion of stained cells" calculated? How many areas per tissue were stained for histo-pathological evaluation? How many images were taken for each of the tissue sections? How was "staining intensity" determined? On what basis did the authors use "30%" as the cutoff to determine positivity of EMP staining? Please explain with appropriate references.

Reviewer \#2: Authors investigated the relationship between the expression of EMP1/2/3 and clinicopathological features of phyllodes tumors, and showed EMP expression is reduced in the epithelial region, while it is increase in the stromal region, along with increasing histologic grade.

\<major comments=\"\"\>

1\) Immunohistochemical staining is quite essential for this study, and its procedure must be standard to obtain solid data. Authors did not use any first antibodies for control. They should use the same class of non-specific antibodies to check non-specific staining, otherwise they could not tell any difference correctly in their staining.

2\) Histologic grade (mitosis, atypia, cellularity) is generally thought to be the most reliable variable for phyllodes tumors. Although stromal EMP3 is significantly correlated with prognosis in univariate analysis, stromal EMP3 is not significant in multivariate Cox regression analysis, but histologic grade. This data might lead us to the conclusion that EMPs is not necessarily required for the diagnosis of phyllodes tumor.

\<minor comment=\"\"\>

1\) Authors describe about the tissue microarray in materials and methods, but no data was found using tissue microarray. Why?

Reviewer \#3: The manuscript entitled 'Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors Yoon Jin Cha and Ja Seung Koo is a descriptive paper aimed to evaluate the expression of Epithelial membrane proteins (EMPs) EMP1, EMP2, and EMP3 in breast phyllodes tumors, and to investigate their clinical implications. This manuscript demonstrates using EMP3 expression may serve as an independent prognostic factor in phyllodes tumors. They used 185 samples in this study, with 138 benign, 32 borderline, and 15 malignant phyllodes tumors.

The subject is interesting and significant, the approach is correct. This is a generally well-written and easy to follow. The tables and figures presented in this manuscript are clear.

Reviewer \#4: This is a clear, concise report. It will be of value to those interested in the EMP proteins and those investigating the biology of Phyllodes tumors. It is rare to see a report ready for publication on first submission, but this meets all the requirements for publication in PLOS One.

 \</minor\>\</major\>

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1:

Thank you for your valuable comments. We revised the manuscript according to your helpful suggestion.

1\. Were the pathologists blind to the identity of the patients, their clinic-pathological diagnoses, and survival data?

\[Answer\] Yes

2\. Please provide lower magnification images of all the IHC slides -- demonstrating the distribution of EMP staining in the stromal vs epithelial areas.

\[Answer\] We provide the scan power view of all IHC slides as supplementary figure 1. (page 5, line 2-3)

3\. Please provide higher magnification images of all the IHC slides -- demonstrating cell membranous localization of the EMP proteins.

\[Answer\] As there are many EMP positive cases, we provide the representative positive slides with high magnification as supplementary figure 2. (page 5, line 2-3)

4\. How was the "proportion of stained cells" calculated? How many areas per tissue were stained for histo-pathological evaluation? How many images were taken for each of the tissue sections? How was "staining intensity" determined? On what basis did the authors use "30%" as the cutoff to determine positivity of EMP staining? Please explain with appropriate references.

\[Answer\] Proportion of stained cells was evaluated by stained area within the TMA tissue cores. In this study, we used two 5mm tissue cores per each case. Most of stained cases demonstrated homogenous staining pattern.After review of every slides of each case, most representative areas were extracted for TMA construction. Generally, phyllodes tumor smaller than 4-5cm, all tumor content is made into paraffin block and examined with HE slides. Tumors bigger than 6cm, at least one block per centimeter is submitted for diagnosis.

As supplementary figure we submitted, we scanned every TMA slides for taking pictures. In case of high magnification, 9-10 images can be obtained per each core.

Staining intensity is divided by three groups, and defined relatively in each antibody. Generally, in EMP2 and EMP3, weak intensity was recognizable positivity at high magnification (400x). Strong intensity was intense positive that easily recognized under low magnification (12.5x). Moderate intensity was defined between weak and strong intensity. In EMP1, expression intensity tended to be generally strong, most of the intensity was 2 or 3.

We applied the staining scoring system from the previous study (PMID: 19762066). In PTs, EMPs were homogenously stained in most of cases, so in many cases, positivity was determined by staining intensity.

Reviewer \#2: Authors investigated the relationship between the expression of EMP1/2/3 and clinicopathological features of phyllodes tumors, and showed EMP expression is reduced in the epithelial region, while it is increase in the stromal region, along with increasing histologic grade.

Thank you for your valuable comments. We revised the manuscript according to your helpful suggestion.

1\) Immunohistochemical staining is quite essential for this study, and its procedure must be standard to obtain solid data. Authors did not use any first antibodies for control. They should use the same class of non-specific antibodies to check non-specific staining, otherwise they could not tell any difference correctly in their staining.

\[Answer\] We already and always used the positive and negative controls when we set up the appropriate dilution of antibody. Accordingly, we revised the method IHC section. (page 4, line 27-28)

2\) Histologic grade (mitosis, atypia, cellularity) is generally thought to be the most reliable variable for phyllodes tumors. Although stromal EMP3 is significantly correlated with prognosis in univariate analysis, stromal EMP3 is not significant in multivariate Cox regression analysis, but histologic grade. This data might lead us to the conclusion that EMPs is not necessarily required for the diagnosis of phyllodes tumor.

\[Answer\] We absolutely agree with your comment. We also found that the clinical impact of this study and the data might be not that significant, But there was no preceding data of EMP and PT, we wanted to investigate the expression of EMPs in PTs, and found that stromal EMPs are increasingly expressed along with histologic grade of PT, and stromal EMP3 could be an prognostic factor. We hope that our result might help other investigators studying EMPs.

1\) Authors describe about the tissue microarray in materials and methods, but no data was found using tissue microarray. Why?

\[Answer\] All the data in result section is the IHC and statistical results using TMA

Reviewer \#3: The manuscript entitled 'Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors Yoon Jin Cha and Ja Seung Koo is a descriptive paper aimed to evaluate the expression of Epithelial membrane proteins (EMPs) EMP1, EMP2, and EMP3 in breast phyllodes tumors, and to investigate their clinical implications. This manuscript demonstrates using EMP3 expression may serve as an independent prognostic factor in phyllodes tumors. They used 185 samples in this study, with 138 benign, 32 borderline, and 15 malignant phyllodes tumors.

The subject is interesting and significant, the approach is correct. This is a generally well-written and easy to follow. The tables and figures presented in this manuscript are clear.

\[Answer\] Thank you for your comments.

Reviewer \#4: This is a clear, concise report. It will be of value to those interested in the EMP proteins and those investigating the biology of Phyllodes tumors. It is rare to see a report ready for publication on first submission, but this meets all the requirements for publication in PLOS One.

\[Answer\] Thank you for your comments.
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Submitted filename: Reviewer_answer.docx

###### 

Click here for additional data file.
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have responded to all of this reviewer\'s comments. This reviewer is satisfied with the responses and the manuscript may be accepted.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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